ICDx is a next-generation hormone testing platform based on novel high-affinity immunocomplex antibodies. It offers a faster, more accurate, and cost-effective alternative to conventional diagnostic methods — opening the door to more accessible and personalized healthcare.
Why Current Hormone Testing Falls Short
Overly complex methods
Current hormone diagnostics rely on a combination of mass spectrometry, competitive immunoassays, and mathematical calculations — making them technically demanding.
High cost, long turnaround
These traditional systems are expensive to operate and slow to deliver results, limiting their use in routine or point-of-care settings.
Insufficient sensitivity
Existing immunoassays suffer from low sensitivity and low specificity, limiting the utility in reliably measuring low concentration samples.
Our solution: What makes ICDx different
Simplified assay format
ICDx replaces the traditional multi-method process with one simple immunoassay.
Faster and affordable
Due to the one assay-setup, the ICDx platform is cheaper and delivers results faster than the traditional methods.
High sensitivity and specificity
Our high-performing immunocomplex assays enable sensitive detection of hormones at clinically relevant levels, supporting more precise and personalized diagnostics.
How it works
No binding
The anti-immunocomplex antibody does not bind in the absence of the specific hormone.
Immunocomplex binding
The anti-immunocomplex antibody binds to the hormone-antibody complex.
Signal readout
The signal readout is simple, where a signal increase indicates an increased hormone concentration.
From Concept to Commercialization
Project status
We are currently conducting proof-of-concept and feasibility studies in laboratory settings. Our goal is to validate assay performance, optimize conditions, and lay the groundwork for future product development and regulatory approval. In addition, we are expanding our technology by developing immunocomplex antibodies toward new hormone targets.